Harnessing QSAR and machine learning for the design of hepatocellular carcinoma inhibitors; experimental validation of the cytotoxicity of new compounds against HepG2 cells
Medicine in Drug Discovery · 2026-08 · 31 · 100260
DOI: 10.1016/j.medidd.2026.100260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine in Drug Discovery, 2026-08. Verfasst von Saba Ali und 9 weiteren Autor:innen. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Thailand Science Research and Innovation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Thailand Science Research and Innovation
Zitieren
APA
Ali, S., Putra, I. D., Aremu, A. J., Jit-aree, P., Limpachayaporn, P., Boonsombat, J., Ruchirawat, S., Wolschann, P., Maitarad, P., & Rungrotmongkol, T. (2026). Harnessing QSAR and machine learning for the design of hepatocellular carcinoma inhibitors; experimental validation of the cytotoxicity of new compounds against HepG2 cells. Medicine in Drug Discovery, 31, 100260. https://doi.org/10.1016/j.medidd.2026.100260
Vancouver
Ali S, Putra ID, Aremu AJ, Jit-aree P, Limpachayaporn P, Boonsombat J, et al. Harnessing QSAR and machine learning for the design of hepatocellular carcinoma inhibitors; experimental validation of the cytotoxicity of new compounds against HepG2 cells. Medicine in Drug Discovery. 2026;31:100260. doi:10.1016/j.medidd.2026.100260
BibTeX
@article{Ali2026,
author = {Ali, Saba and Putra, Ismail Dwi and Aremu, Ayokanmi Joseph and Jit-aree, Peerada and Limpachayaporn, Panupun and Boonsombat, Jutatip and Ruchirawat, Somsak and Wolschann, Peter and Maitarad, Phornphimon and Rungrotmongkol, Thanyada},
title = {Harnessing QSAR and machine learning for the design of hepatocellular carcinoma inhibitors; experimental validation of the cytotoxicity of new compounds against HepG2 cells},
journal = {Medicine in Drug Discovery},
year = {2026},
volume = {31},
pages = {100260},
doi = {10.1016/j.medidd.2026.100260}
}
EUVIMED